Merck wins US FDA OK for boceprevir, beating Vertex in hep C race
This article was originally published in Scrip
Not even the superstition of Friday the 13th could stop Merck from having good luck on 13 May when the US FDA approved the Whitehouse Station, New Jersey pharma's hepatitis C virus (HCV) treatment Victrelis (boceprevir) – beating rival Vertex Pharmaceuticals to the finish line with the first new therapy in about a decade for the viral disease, which affects about 3.2 million people in the US, causing inflammation of the liver, which can lead to diminished function or even failure.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.